Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.

The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis.